Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6184100 | 1.00 | FFAR1 (0.51) | FFAR1CYP2D6KMT2AMEN1TSHR | |
| SCHEMBL25000121 | 0.83 | CYP2D6 (0.43) | CYP2D6KMT2AMEN1TSHRCYP3A4 | |
| SCHEMBL31105377 | 0.83 | CYP2D6 (0.43) | CYP2D6KMT2AMEN1TSHRCYP3A4 | |
| SCHEMBL5190470 | 0.80 | GAA (0.47) | CYP2D6KMT2AMEN1TSHRCYP3A4 | |
| SCHEMBL27952439 | 0.79 | CYP2D6 (0.46) | CYP2D6KMT2AMEN1TSHRCYP3A4 | |
| SCHEMBL15665132 | 0.79 | CYP2D6 (0.46) | CYP2D6KMT2AMEN1TSHRCYP3A4 | |
| SCHEMBL15923278 | 0.79 | CYP2D6 (0.46) | CYP2D6KMT2AMEN1TSHRCYP3A4 | |
| SCHEMBL23043010 | 0.79 | MEN1 (0.47) | CYP2D6KMT2AMEN1TSHRCYP3A4 | |
| SCHEMBL24696382 | 0.78 | OPRL1 (0.45) | CYP2D6KMT2AMEN1TSHRCYP3A4 | |
| SCHEMBL3396327 | 0.78 | CYP2D6 (0.45) | CYP2D6KMT2AMEN1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140904-B1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6800636-B2 | FOR THERAPY OF CANCER | SCHERING CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-20030040520-A1 | Farnesyl protein transferase inhibitors | GUZI TIMOTHY (US) | 2003-02-27 | — | — | US | disclosed |
| US-6362188-B1 | ANTICANCER AGENTS | SCHERING CORPORATION | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040520-A1 | Farnesyl protein transferase inhibitors | FNTA, FNTB, CETP | FFAR1 1254/4885CYP2D6 3760/4885KMT2A 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.